Literature DB >> 3117449

Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition.

S Loche1, M Cappa, P Borrelli, A Faedda, A Crinò, S G Cella, R Corda, E E Müller, C Pintor.   

Abstract

We have evaluated the plasma GH response to a single injection of 1 microgram/kg of GH-releasing hormone (GHRH)-40 in 15 obese children and 15 age-matched control children. Most of the obese children showed a subnormal plasma GH response to GHRH and the mean plasma GH integrated area (IC-GH) following stimulation was significantly smaller in obese than control children. Plasma somatomedin-C (SM-C) levels were significantly higher in obese than control children, and were negatively correlated with the peak plasma GH levels (r = -0.616, P less than 0.01) and the IC-GH (r = -0.554, P less than 0.02) after GHRH. Non-esterified fatty acids (NEFA) and fasting plasma insulin levels were also elevated in obese children, but did not correlate with the extent of plasma GH response to GHRH. These data confirm previous observations on the refractoriness of obese children to release GH after GHRH, and imply that it may be due to the feedback inhibition operated by the elevated plasma levels of SM-C.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117449     DOI: 10.1111/j.1365-2265.1987.tb01139.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

Review 1.  Minor head injury.

Authors:  T F Beattie
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

2.  Reduced levels of growth hormone, insulin-like growth factor-I and binding protein-3 in patients with shunted hydrocephalus.

Authors:  T Löppönen; A L Saukkonen; W Serlo; P Tapanainen; A Ruokonen; M Knip
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

3.  Secretion of growth hormone releasing hormone in obese children.

Authors:  S Loche; S Balzano; M Bozzola; A Moretta; S Pintus; A Faedda; A Muntoni; D Carta; C Pintor
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

4.  The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.

Authors:  S Loche; C Pintor; P Cambiaso; A Lampis; D Carta; R Corda; M Cappa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

5.  Effect of an obesity prevention program focused on motivating environments in childhood: a school-based prospective study.

Authors:  Y Yang; B Kang; E Y Lee; H K Yang; H-S Kim; S-Y Lim; J-H Lee; S-S Lee; B-K Suh; K-H Yoon
Journal:  Int J Obes (Lond)       Date:  2017-02-20       Impact factor: 5.095

6.  Somatic growth of lean children: the potential role of sleep.

Authors:  Yan-Rui Jiang; Karen Spruyt; Wen-Juan Chen; Xiao-Ming Shen; Fan Jiang
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

7.  GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.

Authors:  A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

8.  Abnormal development of the sella turcica and lack of pituitary visualization in a patient with partial hypopituitarism.

Authors:  M Scacchi; G Alé; P Silvestri; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

9.  Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance.

Authors:  U Eiholzer; R Gisin; C Weinmann; S Kriemler; H Steinert; T Torresani; M Zachmann; A Prader
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

10.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.